Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA with CV01 Ultrasound in Recurrent High Grade Glioma
NCT05362409Phase 1Completed
- Sponsor
- Alpheus Medical
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aminolevulinic acid in high-grade glioma (HGG), sponsored by Alpheus Medical. Primary endpoints: Incidence of adverse events at 12 Months and Maximum Tolerable Duration at 12 Months. Started Jun 2022; status: completed.
02
Drugs
aminolevulinic acid
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT05362409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362409.